HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $20
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $27 to $20.
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $27 to $20.
